DOI kodi: 10.52340/ekonomisti.2026.02.15

Expanded Summary

The European Union’s pharmaceutical sector stands at a historic crossroads, undergoing its most significant legislative overhaul in over two decades. The existing regulatory framework, largely established in 2004, has struggled to remain resilient amid rapid scientific advancement, global supply chain vulnerabilities, and escalating healthcare costs. While Europe has successfully fostered life-saving innovations, the COVID-19 pandemic exposed critical systemic weaknesses, including chronic medicine shortages and a stark 90% disparity in access to medicine between Western and Eastern Member States.

The 2020 "Pharmaceutical Strategy for Europe" and the subsequent legislative package introduced by the European Commission in 2023 aim to harmonize these conflicting pressures. This research analyzes the proposed transition from a static, "one-size-fits-all" incentive model to a dynamic, performance-based modular system designed to ensure that no patient is left behind, regardless of their geographic location within the Union.

The primary objective of this study is to provide a comparative analysis of the legislative proposals put forward by the European Commission (2023) and the amendments adopted by the European Parliament in April 2024. The research focuses on three pivotal pillars:

• The recalibration of Regulatory Data Protection (RDP) for standard medicinal products.
• The tiering of incentives for Orphan Medicinal Products (OMP).
• The introduction of novel financial instruments to combat Antimicrobial Resistance (AMR).

The methodology utilizes a qualitative, comparative-legal approach, examining primary EU legislative documents, regulatory impact assessments, and peer-reviewed academic literature. By contrasting the Commission’s "logistics-first" approach with the Parliament’s "science-first" amendments, this study identifies key areas of institutional divergence and their potential economic impacts on the global pharmaceutical market.

Central to the reform is the reconstruction of the Regulatory Data Protection (RDP) system. Under current laws, innovators enjoy a static "8+2" protection period (8 years of data protection plus 2 years of market protection). The Commission’s proposal suggests a fundamental shift: reducing the baseline RDP to 6 years, while allowing companies to "earn back" exclusivity through social and clinical contributions.

Extensions include:

• +2 years for launching and ensuring continuous supply in all 27 Member States.
• +6 months for products addressing an Unmet Medical Need (UMN).
• +6 months for conducting comparative clinical trials.
• +1 year for a new therapeutic indication with significant clinical benefit.

The European Parliament’s 2024 amendments, however, proposed a higher baseline of 7.5 years, arguing that the Commission’s "all-member-state" requirement is logistically unfeasible for many smaller biotech firms. This research evaluates how these competing baselines influence the "break-even" point for R&D investments and the potential for generic competition to enter the market earlier.

The reform introduces a sophisticated hierarchy for rare disease treatments. While the current 10-year market exclusivity for orphan drugs has been successful in bringing products to market, investments have often clustered around "low-hanging fruit"—rare diseases with relatively larger patient populations.

To steer R&D toward the most neglected areas, the reform introduces the "High Unmet Medical Need" (HUMN) status. Products achieving this status would receive up to 11 years of exclusivity (under the Parliament’s version), while "well-established use" orphan products would see their protection reduced. This study explores the socio-economic implications of this tiering, specifically how it may incentivize breakthrough gene therapies for ultra-rare conditions while managing the financial sustainability of national health budgets.

Addressing the "silent pandemic" of Antimicrobial Resistance (AMR) requires a departure from traditional volume-based sales models. Because new antibiotics must be used sparingly to maintain efficacy, they are inherently unprofitable.

To bridge this "market failure," the reform proposes the Transferable Data Exclusivity Voucher (TEV). A TEV allows the developer of a priority antimicrobial to extend the RDP of any other product in its portfolio by 6 to 12 months, or to sell that voucher to another firm. This research assesses the fierce debate surrounding TEVs: while they provide a powerful pull-incentive for antibiotic R&D, critics argue they place an undue burden on national payers by delaying generic entry for unrelated "blockbuster" drugs. The paper also examines the Parliament’s favored alternative: the "Subscription Model" (or Netflix model), which provides developers with a fixed annual fee regardless of sales volume, thereby decoupling profit from the quantity of antibiotics sold.

The transition to a modular system represents a paradigm shift in EU health policy. For the first time, intellectual property-related rewards are directly tied to patient access and clinical transparency. However, the study identifies significant risks. For Small and Medium Enterprises (SMEs), which represent the backbone of European biotech innovation, a reduced baseline RDP could create "death valleys" in financing.

Furthermore, the research evaluates the geopolitical dimension. As the US (via the Inflation Reduction Act) and China intensify their own pharmaceutical incentives, Europe’s reform must ensure it does not inadvertently trigger a "flight of capital." The study suggests that while modularity is necessary for equity, the final "Trilogue" agreement must ensure that the complexity of the "bonus" system does not create administrative paralysis for the European Medicines Agency (EMA).

The EU pharmaceutical reform is a courageous attempt to reconcile the irreconcilable: the need for high-cost innovation and the demand for affordable, universal healthcare. This paper concludes that the success of the reform hinges on the "predictability" of the incentives. If the conditions for earning extensions are too burdensome or legally uncertain, the EU risks losing its competitive edge. However, if implemented correctly, the 2024 reform will establish a global gold standard for "socially responsible" pharmaceutical regulation, ensuring that the fruits of scientific progress reach every corner of the Union.

Keywords: EU Pharmaceutical Reform, Modular Incentives, Regulatory Data Protection (RDP), Orphan Drugs, Antimicrobial Resistance (AMR), Market Exclusivity, Patient Access.